Jacques Youssef, MD
Nephrology · Murray, KYNPI 1699963835
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,451 of the $2,842 with a category attached, or 86.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 148 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$571
- AstraZeneca$341
- Vifor Pharma, Inc.$306
- Travere Therapeutics, Inc.$225
- OPKO Pharmaceuticals, LLC$157
- Amgen$156
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$2007%
- Food & beverage$2,45186%
- Education$1917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 29 | $571 |
| AstraZeneca | 21 | $341 |
| Vifor Pharma, Inc. | 8 | $306 |
| Travere Therapeutics, Inc. | 11 | $225 |
| OPKO Pharmaceuticals, LLC | 10 | $157 |
| Amgen(2 entities) | 10 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $138 |
| Bayer | 8 | $120 |
| Mallinckrodt Hospital Products Inc. | 5 | $112 |
| Ardelyx, Inc. | 6 | $112 |
| GSK | 6 | $101 |
| Aurinia Pharma U.S., Inc. | 3 | $81 |
| Novartis | 3 | $61 |
| Lundbeck LLC | 3 | $52 |
| Calliditas Therapeutics US Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Mallinckrodt Enterprises LLC | 2 | $43 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Shield Therapeutics Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Sanofi | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
How this compares
$2,842 in reported general payments places this provider in the 65th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 70 | $135,504 |
| FarxigaDapagliflozin Propanediol | 77 | $68,192 |
| JardianceEmpagliflozin | 57 | $54,212 |
| VelphoroSucroferric Oxyhydroxide | 14 | $47,793 |
| RayaldeeCalcifediol | 12 | $13,332 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $11,446 |
| Sevelamer Carbonate | 55 | $5,280 |
| Allopurinol | 377 | $4,360 |
| Calcitriol | 314 | $4,064 |
| Febuxostat | 13 | $3,763 |
| Bumetanide | 70 | $2,579 |
| Hydralazine Hcl | 155 | $2,165 |
| Mycophenolate Mofetil | 12 | $2,036 |
| Potassium Chloride | 66 | $1,598 |
| Metolazone | 47 | $1,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $341 | $68,19277 claims |
| Boehringer IngelheimJardiance | $47 | $54,21257 claims |
| Fresenius USA Marketing, Inc.Velphoro | $571 | $47,79314 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $157 | $13,33212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Murray
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Javier Neyra LozanoLexington$181K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Ravinder BhagrathPikeville$84K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Sadiq AhmedLexington$17K
- Muhammad FarhanMt Sterling$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.